Dermatologic drug reactions

被引:31
作者
McKenna, JK [1 ]
Leiferman, KM [1 ]
机构
[1] Univ Utah, Sch Med 4B454, Dept Dermatol, Salt Lake City, UT 84132 USA
关键词
D O I
10.1016/j.iac.2004.03.007
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Adverse reactions to medications are estimated to occur in 0.1% to 1% of patients using systemic medications. Certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and anticonvulsants, have drug eruption rates approaching 1% to 5% [1]. Approximately 30 drug-related cutaneous reaction patterns are described (Box 1) [2]. In addition, the same medication may evoke a different reaction pattern in different individuals. This fact makes identification of the offending agent difficult for primary care physicians, allergists, and dermatologists. An estimated 2% of medication-related skin eruptions meet the World Health Organization definition of a serious reaction [3]. Of these reactions, several constitute truly life-threatening emergencies and need rapid accurate diagnosis and intervention. This review describes common, serious, and distinctive drug reaction patterns in skin. The pathogenesis of drug allergy is discussed with respect to immunologic mechanisms; nonimmunologic drug reactions may also occur. Basic classification of skin lesions is reviewed; however, this discussion centers on identification of the most common or serious cutaneous reaction patterns.
引用
收藏
页码:399 / +
页数:26
相关论文
共 70 条
[61]  
Shin H T, 2001, Curr Probl Pediatr, V31, P207, DOI 10.1067/mps.2001.117632
[62]  
SMITH EP, 1993, J AM ACAD DERMATOL, V29, P879
[63]  
Steckelings UM, 2001, ACTA DERM-VENEREOL, V81, P321
[64]   Colchicine in dermatology [J].
Sullivan, TP ;
King, LE ;
Boyd, AS .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 39 (06) :993-999
[65]   Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN - The University of Miami experience [J].
Trent, JT ;
Kirsner, RS ;
Romanelli, P ;
Kerdel, FA .
ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :39-43
[66]  
VANDERVEN AJM, 1994, J ANTIMICROB CHEMOTH, V34, P1, DOI 10.1093/jac/34.1.1
[67]   Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin [J].
Viard, I ;
Wehrli, P ;
Bullani, R ;
Schneider, P ;
Holler, N ;
Salomon, D ;
Hunziker, T ;
Saurat, JH ;
Tschopp, J ;
French, LE .
SCIENCE, 1998, 282 (5388) :490-493
[68]  
Wakelin SH, 1998, BRIT J DERMATOL, V138, P310
[69]   Mechanisms of drug-induced lupus .4. Comparison of procainamide and hydralazine with analogs in vitro and in vivo [J].
Yung, R ;
Chang, S ;
Hemati, N ;
Johnson, K ;
Richardson, B .
ARTHRITIS AND RHEUMATISM, 1997, 40 (08) :1436-1443
[70]   Management of urticaria: A consensus report [J].
Zuberbier, T ;
Greaves, MW ;
Juhlin, L ;
Merk, H ;
Stingl, G ;
Henz, BM .
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2001, 6 (02) :128-131